Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Up 56.9% in July

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 2,273,103 shares, a growth of 56.9% from the July 15th total of 1,448,757 shares. Based on an average daily trading volume, of 835,918 shares, the days-to-cover ratio is currently 2.7 days. Currently, 3.0% of the company’s shares are sold short.

Nautilus Biotechnology Stock Up 5.8%

Shares of NASDAQ:NAUT opened at $0.90 on Thursday. The firm has a fifty day moving average of $1.60 and a two-hundred day moving average of $2.32. The firm has a market capitalization of $114.72 million, a P/E ratio of -2.00 and a beta of 0.87. Nautilus Biotechnology has a 12-month low of $0.62 and a 12-month high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings results on Tuesday, July 28th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.10 million.

Insider Buying and Selling

In other Nautilus Biotechnology news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the completion of the sale, the insider directly owned 971,885 shares of the company’s stock, valued at approximately $2,283,929.75. This represents a 83.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 41.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NAUT. CTC Alternative Strategies Ltd. acquired a new stake in shares of Nautilus Biotechnology during the 1st quarter valued at about $48,000. Garde Capital Inc. acquired a new position in Nautilus Biotechnology in the fourth quarter worth approximately $35,000. Hudson Bay Capital Management LP acquired a new position in Nautilus Biotechnology in the fourth quarter worth approximately $37,000. Public Employees Retirement System of Ohio bought a new position in Nautilus Biotechnology during the first quarter valued at approximately $75,000. Finally, Virtu Financial LLC raised its position in Nautilus Biotechnology by 19.6% during the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock valued at $46,000 after acquiring an additional 3,849 shares in the last quarter. 50.71% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.00.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.